Abstract:In the author's institution, 2254 patients with hepatocellular carcinoma (HCC) have been treated during 1958-1994. The overall 5-year survival increased from 5.4% (1958-1970), to 11.9% (1971-1982), to 46.2% (1983-1984), which correlated well with the increasing proportion of small HCC in the series (2.6%, 12.1%, and 33.4%, respectively); with the increasing percentage of limited resection (3.1%, 32.2%, and 58.3%); with the increasing number of re-resections for recurrence (0, 27, and 114 patients); and with the increasing number of second stage resections (0, 5, and 67 patients). In our institution, surgical approaches that resulted in significantly prolonging survival included: small HCC resection, re-resection, and cytoreduction followed by sequential resection for initially unresectable HCC. Experience in these 3 aspects suggests: (a) Small HCCs are mainly found by screening using AFP and ultrasonography (US) in a high risk population, and limited resection is the best treatment in patients with compensated liver cirrhosis, the 5-year survival after resection being 62.9% (n = 549). (b) Postoperative monitoring using AFP/US every 2-3 months for 5-10 years after curative resection is needed to detect subclinical recurrence. Limited re-resection is indicated for liver recurrence less than 3 nodules, and lung lobectomy is of proven merit to prolong survival for solitary lung metastasis. Re-resection of subclinical recurrence has resulted in a 10-20% further increase in 5-year survival after curative resection. (c) Palliative surgery other than resection such as hepatic artery ligation (HAL) and cannulation with arterial infusion (HAI), cryosurgery, etc. are superior to palliative resection with residual cancer. (d) Cytoreduction and sequential resection have provided hope for localized unresectable HCC, particularly in the right cirrhotic liver. Multimodality combination treatments such as HAL+HAI+radioimmunotherapy/regional radiotherapy are acceptable cytoreductive therapies. Repeated transcatheter hepatic arterial chemoembolization (TACE) is an alternative nonsurgical approach. Sequential resection is important to eradicate residual cancer after cytoreduction. The 5-year survival of 72 patients with cytoreduction and sequential resection for initially unresectable HCC was 62.1% and resulted in improving 5-year survival in the entire series of unresectable HCC over the 3 periods from 0% to 7.4% to 25.7%, respectively. However, multicentric origin and tumor invasiveness are two major targets to be studied in the control of recurrence and metastasis.

Resection of huge hepatocellular carcinoma by two-stage operation: Report of 48 cases

Surgical Treatment for Giant Primary Liver Cancer:A Report of 146 Cases

Systematic sequential therapy for <i>ex vivo</i> liver resection and autotransplantation: A case report and review of literature

Conversion of Surgically Verified Unresectable to Resectable Hepatocellular Carcinoma

Three Decades' Experience In Surgery Of Hepatocellular Carcinoma

The Role of Targeting Therapy in Cytoreduction and Sequential Resection of Unresectable Hepatocellular Carcinoma

Surgical Treatment of Hepatocellular Carcinoma Originating from Caudate Lobe—a Report of 39 Cases

Multimodality treatment and two-stage resection for unresectable hepatocellular carcinoma--experimental and clinical studies]

Cytoreduction and Sequential Resection for Surgically Verified Unresectable Hepatocellular Carcinoma: Evaluation with Analysis of 72 Patients

Surgical Treatment of Recurrent Hepatocellular Carcinoma.

Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization

An Approach Improving Long-Term Outcome of Surgery for Hepatocellular Carcinoma: Analysis of 113 Patients Surviving More Than Five Years

Systematic Review of Single Large and/or Multinodular Hepatocellular Carcinoma: Surgical Resection Improves Survival.

[Influence of Different Treatment Modalities on Survival of Patients with Two -Stage Resection of Unresectable Hepatocellular Carcinoma].

Evolution of Surgery in the Treatment of Hepatocellular-Carcinoma from the 1950s to the 1990S

[Surgical Treatment of 1450 Patients with Hepatocellular Carcinoma].

Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report

Minimally Invasive Treatment of Large HCC-Reevaluation Hepatic Artery Ligation and Intubation to Large HCC

Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma

Experience with Liver Resection after Hepatic Arterial Chemoembolization for Hepatocellular Carcinoma.

Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy